Sanofi, Regeneron successful in phase II asthma trial
The investigational IL-33 antibody REGN3500 met its primary and secondary endpoints in the joint phase II proof-of-concept trial.
Read More
Tag: REGN3500
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
